Prostate radiotherapy should be considered for men with low metastatic burden
Our latest STOPCAP systematic review and meta-analysis has concluded that prostate radiotherapy should be considered for men with low metastatic burden, hormone-sensitive prostate cancer (HSPC).
Although the results overall showed that the addition of prostate radiotherapy to ADT did not help men with metastatic HSPC to live longer, it did show an approximate 10% benefit on biochemical progression at three years. The benefit of prostate radiotherapy varied depending on metastatic burden; men with fewer than five bone metastases (low burden) receiving the greatest benefit from radiotherapy, including a 7% improvement in survival.
The analysis included results from two trials (HORRAD, STAMPEDE) and 2126 men. We obtained pre-publication, unpublished, and harmonised results directly from the investigators
- Click here for summary of the results
- Full publication here Burdett et al. European Urology, 2019; https://doi.org/10.1016/j.eururo.2019.02.003